TY - JOUR
T1 - Skin conditions in early Parkinson's disease
AU - Dinesh, Deepika
AU - Lee, Jong Soo
AU - Gao, Xiang
AU - Palacios, Natalia
N1 - Funding Information:
Data were obtained from the PPMI database ( www.ppmi-info.org/data ). PPMI is an observational, international, multicenter study aimed at identifying PD progression biomarkers and is a public-private partnership sponsored by the Michael J. Fox Foundation and other funding partners [ 23 ]. Data was downloaded from the PPMI database in October 2016. Data at baseline (BL) and on first screening visit (SC) on 423 recently-onset drug-naïve PD participants with dopamine transporter (DAT) deficits and complete enrollment dates and 196 HC with no significant neurological deficits, no first-degree relatives with PD and over 30 years of age were used for this analysis. Details on inclusion and exclusion criteria for PD participants and healthy controls (HC) in the PPMI have been described previously [ 23 ].
Funding Information:
Natalia Palacios received funding from the NIH (R01NS097723). Xiang Gao received funding from the NINDS: 1R01NS102735-01A1. Data used in the preparation of this article were obtained from the Parkinson's Progression Markers Initiative (PPMI) database (www.ppmi-info.org/data). For up-to-date information on the study, visit ppmi-info.org. PPMI is sponsored by the Michael J. Fox Foundation for Parkinson's Research (MJFF) and is co?funded by MJFF, AbbVie, Allergan, Avid Radiopharmaceuticals, Biogen, BioLegend, Bristol-Myers Squibb, Celgene, Denali, Eli Lilly & Co. F. Hoffman?La Roche, Ltd, GE Healthcare, Genentech, GlaxoSmithKline, Lundbeck, Merck, Meso Scale Discovery, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanofi Genzyme, Servier, Takeda, Teva, UCB, Verily, Voyager Therapeutics, and Golub Capital. For up-to-date information on the study, visit ppmi-info.org.
Funding Information:
Xiang Gao received funding from the NINDS: 1R01NS102735-01A1.
Funding Information:
Natalia Palacios received funding from the NIH (R01NS097723).
Publisher Copyright:
© 2021
PY - 2021/3
Y1 - 2021/3
N2 - Objective: Skin conditions have been associated with increased risk of Parkinson's disease (PD). Little is known about clinical and biomarker differences according to presence of skin conditions among PD patients. Studying these differences might provide insight into PD pathogenesis. Methods: We examined the association between common skin conditions and risk of PD in a case-control study of 423 early drug-naïve PD cases and 196 healthy controls (HC) in the Parkinson's Progression Markers Initiative (PPMI). Among PD participants, we examined if skin conditions were associated with clinical and PD-relevant biomarkers. Results: Skin conditions occurred more frequently among PD participants (41%) relative to HC (32%). In multivariate analyses, we observed an association between any skin condition and PD (OR = 1.49, 95% CI = 1.03–2.16) and basal cell carcinoma and PD (OR = 2.05, 95% CI = 1.02–4.08). PD participants who reported skin conditions were older (OR = 1.68, 95% CI = 1.21–2.35) more educated (OR = 1.70, 95% CI = 0.99–2.91), had higher Semantic Fluency Test (SFT) scores (OR = 1.45, 95% CI = 1.07–1.96) and Hopkins Verbal Learning Test (HVLT) retention scores (OR = 1.55, 95% CI = 1.09–2.22) compared to PD patients without skin conditions. None of the associations remained significant after Bonferroni correction for multiple comparisons. Conclusions: We observed a positive association between any skin condition as well as basal cell carcinoma and PD. PD participants with skin conditions were older, more educated, had higher SFT and HVLT retention scores compared to those without skin conditions. However, all associations were no longer significant after Bonferroni multiple comparisons correction. Observed associations should be confirmed in larger, longitudinal studies.
AB - Objective: Skin conditions have been associated with increased risk of Parkinson's disease (PD). Little is known about clinical and biomarker differences according to presence of skin conditions among PD patients. Studying these differences might provide insight into PD pathogenesis. Methods: We examined the association between common skin conditions and risk of PD in a case-control study of 423 early drug-naïve PD cases and 196 healthy controls (HC) in the Parkinson's Progression Markers Initiative (PPMI). Among PD participants, we examined if skin conditions were associated with clinical and PD-relevant biomarkers. Results: Skin conditions occurred more frequently among PD participants (41%) relative to HC (32%). In multivariate analyses, we observed an association between any skin condition and PD (OR = 1.49, 95% CI = 1.03–2.16) and basal cell carcinoma and PD (OR = 2.05, 95% CI = 1.02–4.08). PD participants who reported skin conditions were older (OR = 1.68, 95% CI = 1.21–2.35) more educated (OR = 1.70, 95% CI = 0.99–2.91), had higher Semantic Fluency Test (SFT) scores (OR = 1.45, 95% CI = 1.07–1.96) and Hopkins Verbal Learning Test (HVLT) retention scores (OR = 1.55, 95% CI = 1.09–2.22) compared to PD patients without skin conditions. None of the associations remained significant after Bonferroni correction for multiple comparisons. Conclusions: We observed a positive association between any skin condition as well as basal cell carcinoma and PD. PD participants with skin conditions were older, more educated, had higher SFT and HVLT retention scores compared to those without skin conditions. However, all associations were no longer significant after Bonferroni multiple comparisons correction. Observed associations should be confirmed in larger, longitudinal studies.
UR - http://www.scopus.com/inward/record.url?scp=85100403195&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100403195&partnerID=8YFLogxK
U2 - 10.1016/j.parkreldis.2021.01.018
DO - 10.1016/j.parkreldis.2021.01.018
M3 - Article
C2 - 33549915
AN - SCOPUS:85100403195
SN - 1353-8020
VL - 84
SP - 40
EP - 46
JO - Parkinsonism and Related Disorders
JF - Parkinsonism and Related Disorders
ER -